Karyopharm Therapeutics

343 articles about Karyopharm Therapeutics

• Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition

  11/4/2021

  Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that an abstract detailing new data from a Phase 2 study evaluating selinexor.

• Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business Highlights

  11/3/2021

  Karyopharm Therapeutics Inc. today reported financial results for the quarter ended September 30, 2021 and provided business highlights.

• Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 01, 2021

  11/1/2021

  Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 171,300 shares of Karyopharm's common stock to 15 newly-hired employees, with a grant date of October 29, 2021.

• Karyopharm to Report Third Quarter 2021 Financial Results on November 3, 2021

  10/27/2021

  -- Conference Call Scheduled for Wednesday, November 3, 2021, at 8:30 a.m. ET --

• Karyopharm Announces Dosing of First Patient in a Phase 2 Study Investigating Oral Eltanexor in HMA Refractory Myelodysplastic Syndrome

  10/21/2021

   Karyopharm Therapeutics Inc. today announced dosing of the first patient in the Phase 2 expansion of an ongoing open-label Phase 1/2 study investigating eltanexor, a novel oral, Selective Inhibitor of Nuclear Export (SINE) compound

• Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2021

  10/1/2021

  Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 147,300 shares of Karyopharm's common stock to 21 newly-hired employees, with a grant date of September 30, 2021.

• Karyopharm Announces Upcoming Virtual Investor Conference Participation in September 2021

  9/7/2021

  Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that Richard Paulson, President and Chief Executive Officer, will participate in the following virtual investor conferences in September.

• Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 01, 2021

  9/1/2021

  Karyopharm Therapeutics Inc. announced that in connection with the hiring of Eleonora Goldberg, Senior Vice President of Global Medical & Scientific Affairs, the Compensation Committee of Karyopharm's Board of Directors granted a stock option to purchase 100,000 shares of Karyopharm's common stock to Dr. Goldberg, with a grant date of August 31, 2021.

• Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results

  8/5/2021

  Karyopharm Therapeutics Inc.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported business highlights and financial results for the quarter ended June 30, 2021.

• Karyopharm Announces Upcoming Virtual Investor Conference Participation - Aug 03, 2021

  8/3/2021

  Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that Richard Paulson, President and Chief Executive Officer, will participate on a speaker panel at the 2021 Wedbush PacGrow Healthcare Virtual Conference titled, "Building Back a Better Commercial Infrastructure – Selling in COVID Times" and participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference.

• Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 02, 2021

  8/2/2021

  Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 74,600 shares of Karyopharm's common stock to 11 newly-hired employees, with a grant date of July 30, 2021.

• Karyopharm to Report Second Quarter 2021 Financial Results on August 5, 2021

  7/29/2021

  Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021.

• Karyopharm Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies in Melanoma and Myelofibrosis

  7/28/2021

  Karyopharm Therapeutics Inc. announced dosing of the first patients in two new company-sponsored Phase 2 and 1/2 clinical studies evaluating XPOVIO®, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export compound in combination with approved therapies in patients with advanced melanoma and in patients with treatment naïve myelofibrosis.

• Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 01, 2021

  7/1/2021

  Karyopharm Therapeutics Inc. announced that in connection with the hiring of Ms. Sohanya Cheng, Senior Vice President, Sales and Commercial Operations, the Compensation Committee of Karyopharm's Board of Directors granted a stock option to purchase 125,000 shares of Karyopharm's common stock to Ms. Cheng, with a grant date of June 30, 2021.

• Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million

  6/24/2021

  Karyopharm Therapeutics Inc. announced the expansion of its royalty agreement with entities managed by HealthCare Royalty Management, LLC for up to $100 million in new financing to support the ongoing development and commercialization of XPOVIO®, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export compound, and for the clinical development of Karyopharm's other programs, including eltanexor.

• Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress

  6/9/2021

  Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that nine abstracts have been selected for virtual presentation, including one oral presentation, at the upcoming European Hematology Association 2021 Virtual Congress taking place June 9-17, 2021.

• Karyopharm Announces Key Changes to Its Commercial Leadership Team

  6/8/2021

  − Sohanya Cheng, Appointed as Head of Sales and Commercial Operations - − Payman Darouian, to Lead Marketing for XPOVIO®.

• Karyopharm Announces XPOVIO® (selinexor) Is Now Available in Additional Strength Tablets

  6/3/2021

  -- Three New Strength Tablets Approved by the FDA: 40 mg, 50 mg and 60 mg -- -- New Tablet Strengths Provide Additional Patient Convenience and Dosing Flexibility --

• Karyopharm Receives Conditional Marketing Authorization in the United Kingdom (UK) for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma

  6/2/2021

  Karyopharm Therapeutics Inc. announced that on May 26, 2021 the UK's Medicines & Healthcare Products Regulatory Agency granted conditional marketing authorization for NEXPOVIO®, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export medicine

• Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2021

  6/1/2021

  Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 24,600 shares of Karyopharm's common stock to six newly-hired employees, with a grant date of May 28, 2021.